Abstract
Background: Depression is a heavily prevalent mental disorder. Symptoms of depression
extend beyond mood, cognition, and behavior to include a spectrum of somatic manifestations in all
organic systems. Changes in sleep and neuroendocrine rhythms are especially prominent, and disruptions
of circadian rhythms have been closely related to the neurobiology of depression. With the
advent of increased research in chronobiology, various pathophysiologic mechanisms have been
proposed, including anomalies of sleep architecture, the effects of clock gene polymorphisms in
monoamine metabolism, and the deleterious impact of social zeitgebers. The identification of these
chronodisruptions has propelled the emergence of several chronotherapeutic strategies, both pharmacological
and non-pharmacological, with varying degrees of clinical evidence.
Methods: The fundamental objective of this review is to integrate current knowledge about the role
of chronobiology and depression and to summarize the interventions developed to resynchronize
biorhythms both within an individual and with geophysical time.
Results: We have found that among the non-pharmacological alternatives, triple chronotherapywhich
encompasses bright light therapy, sleep deprivation therapy, and consecutive sleep phase
advance therapy-has garnered the most considerable scientific interest. On the other hand,
agomelatine appears to be the most promising pharmacological option, given its unique melatonergic
pharmacodynamics.
Conclusion: Research in chronotherapy as a treatment for depression is currently booming. Novel
interventions could play a significant role in adopting new options for the treatment of depression,
with Tripe Cronotherapy standing out as the most promising treatment.
Keywords:
Depression, chronobiology, chronotherapy, chronodisruption, agomelatine, sleep.
Graphical Abstract
[4]
Larios J, Laborde C, Gaviria S. M, Lastre G. Caracterización de Factores de Riesgo Psicosociales Que Inciden En Trastorno Depresivo Mayor En. Adolescentes Cienc Innov Salud 2017; 4(2): 1-8.
[5]
Vera K, Anguisaca K, Davila M, et al. Obesidad en los pacientes con trastornos mentales: aspectos epidemiológicos, etiológicos y prácticos. Rev Latinoam Hipertens 2019; 14(2): 155-9.
[6]
Solimany F, Mohammadi E, Omidfar F. Comparison of cognitive abilities, depression and anxiety of type II diabetic patients with healthy individuals in Isfahan Province in 2015. Rev Latinoam Hipertens 2018; 13(3): 297-304.
[7]
Veintimilla P, Guamán M, Guamán R, et al. Relación entre el grado de severidad de la psoriasis y la depresión. AVFT 2017; 36(6): 153-7.
[9]
Hernández GO, Torres SK, Ávila CE, Livingston CJ, Pinzón MM. Consumos y costos de medicamentos: herramienta para la gestión de suministro del servicio farmacéuticoCienc innov salud 2015; 3(1): 45-52.
[10]
De La Cruz Vargas J A, Dos Santos F, Dyzinger W, Herzog S. Medicina del estilo de vida: trabajando juntos para revertir la epidemia de las enfermedades crónicas en latinoaméricaCienc innov salud 2017; 4(2): 1-7.
[13]
Vera K, Davila M, Gusqui I, Anguisaca K, Lopez M, Salazar R. Función tiroidea y trastornos mentales: una relación subestimada. AVFT 2017; 36(6): 63-7.
[24]
Ángeles-Castellanos M, Rodríguez K, Salgado R, Escobar C. Cronobiología médica. Fisiología y fisiopatología de los ritmos biológicos. Rev Fac Med UNAM 2007; 50(6): 238-41.
[60]
Reyes A, Huailas W, Naranjo R, et al. Cambios cardiometabólicos en trabajadores del área de la salud: papel de la disrupción del sueño. Rev Latinoam Hipertens 2019; 14(2): 230-6.
[94]
Caldelas I, Challet E, Saboureau M, Pevet P. Light and melatonin inhibit in vivo serotonergic phase advances without altering serotonergic-induced decrease of per expression in the hamster suprachiasmatic nucleusJMN 2005; 25(1): 053-64.
[157]
Chávez-Castillo M, Ortega Á, Nava M, et al. Metabolic risk in depression and treatment with selective serotonin reuptake inhibitors are the metabolic syndrome and an increase in cardiovascular risk unavoidable? Vessel Plus 2018; 2(4): 6.
[160]
Taylor D, Sparshatt A, Varma S, Olofinjana O. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studiesBMJ 2014; 348: g1888.
[173]
Sánchez-Betancourt J, Ávila-Costa M, Meza-Amaya A, Ruiz-Vázquez J, Muñiz-Salazar R. Efecto agudo de la melatonina exógena sobre funciones cognitivas, en jóvenes adultos que consumen alcohol. AVFT 2018; 37(5): 434-7.